Abstract:Although RSV has been a high priority for vaccine development, efforts to develop a safe and effective vaccine have yet to lead to a licensed product. Clinical and epidemiologic features of RSV disease suggest there are at least 4 distinct target populations for vaccines, the RSV naïve young infant, the RSV naïve child ≥ 6 months of age, pregnant women (to provide passive protection to newborns), and the elderly. These target populations raise different safety and efficacy concerns and may require different vaccination strategies. The highest priority target population is the RSV naïve child. The occurrence of serious adverse events associated with the first vaccine candidate for young children, formalin inactivated RSV (FI-RSV), has focused vaccine development for the young RSV naïve child on live virus vaccines. Enhanced disease is not a concern for persons previously primed by a live virus infection. A variety of live-attenuated viruses have been developed with none yet achieving licensure. New live-attenuated RSV vaccines are being developed and evaluated that maybe sufficiently safe and efficacious to move to licensure. A variety of subunit vaccines are being developed and evaluated primarily for adults in whom enhanced disease is not a concern. An attenuated parainfluenza virus 3 vector expressing the RSV F protein was evaluated in RSV naïve children. Most of these candidate vaccines have used the RSV F protein in various vaccine platforms including virus-like particles, nanoparticles, formulated with adjuvants, and expressed by DNA or virus vectors. The other surface glycoprotein, the G protein, has also been used in candidate vaccines. We now have tools to make and evaluate a wide range of promising vaccines. Costly clinical trials in the target population are needed to evaluate and select candidate vaccines for advancement to efficacy trials. Better data on RSV-associated mortality in developing countries, better estimates of the risk of long term sequelae such as wheezing after infection, better measures of protection in target populations, and data on the costs and benefits of vaccines for target populations are needed to support and justify funding this process. Addressing these challenges and needs should improve the efficiency and speed of achieving a safe and effective, licensed RSV vaccine.

Advances in understanding RSV glycoproteins: Insights into viral entry and implications for vaccines and therapeutic development

Respiratory syncytial virus entry and how to block it

Respiratory syncytial virus infection and novel interventions

Structural basis for respiratory syncytial virus and human metapneumovirus neutralization

Research Progress in Respiratory Syncytial Virus Vaccines

Current concepts and progress in RSV vaccine development

Biological challenges and technological opportunities for respiratory syncytial virus vaccine development

Development of mRNA vaccines against respiratory syncytial virus (RSV)

New insights for development of a safe and protective RSV vaccine

Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches

An Overview of Respiratory Syncytial Virus Vaccine Development

Impact of Respiratory Syncytial Virus Infection on Host Functions: Implications for Antiviral Strategies

Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years

Respiratory syncytial virus (RSV) disease and prospects for its control

Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus

Respiratory syncytial virus vaccine: where are we now and what comes next?

Revisiting respiratory syncytial virus’s interaction with host immunity, towards novel therapeutics

Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development

Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus

Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines

Strategic priorities for respiratory syncytial virus (RSV) vaccine development